Elaborate about aminoglycosides emphasising it’s use in in ENT

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I now have comprehensive content from multiple authoritative textbooks. Let me compose the full answer.

Aminoglycosides - A Comprehensive Overview with Emphasis on ENT

1. Introduction and Origins

Aminoglycosides are a class of bactericidal antibiotics derived from soil actinomycetes. Streptomycin, the first member, was isolated from Streptomyces griseus. Gentamicin and netilmicin are derived from Micromonospora species - this explains the "-micin" suffix, versus the "-mycin" suffix of streptomycin, tobramycin, kanamycin, and neomycin. Amikacin (a derivative of kanamycin), netilmicin, and plazomicin are semisynthetic products.

Members of the class include:

Streptomycin - oldest; vestibulotoxic > cochleotoxic
Gentamicin - most widely used; vestibulotoxic > cochleotoxic
Tobramycin - most potent against Pseudomonas aeruginosa
Amikacin - broadest spectrum; resistant to most inactivating enzymes
Neomycin - topical use only; highly oto- and nephrotoxic if systemic
Kanamycin, dihydrostreptomycin - largely superseded
Plazomicin - newer semisynthetic; active against aminoglycoside-resistant strains
Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 1308-1310

2. Chemical Structure

Aminoglycosides consist of amino sugars linked to an aminocyclitol ring by glycosidic bonds. They are polycations (highly polar), which governs their pharmacokinetic behavior - they are not absorbed orally, do not cross the blood-brain barrier well, and are renally excreted virtually unchanged.

3. Mechanism of Action

Aminoglycosides are concentration-dependent bactericidal agents. Their action proceeds in several steps:

Outer membrane penetration - drugs diffuse through porin channels in gram-negative bacteria.
Energy-dependent uptake - transport across the cytoplasmic membrane depends on a transmembrane electrical gradient coupled to electron transport. This phase is inhibited by Ca²+, Mg²+, hyperosmolarity, reduced pH, and anaerobic conditions - explaining their poor activity in anaerobic environments and abscesses.
Ribosomal binding - they irreversibly bind the 30S ribosomal subunit, causing misreading of the genetic code and production of aberrant (nonsense) proteins. These faulty proteins insert into the cell membrane, increasing permeability and causing further drug accumulation - a "self-promoted uptake" cycle leading to cell death.

Key pharmacodynamic features:

Concentration-dependent killing: higher peak concentration = faster bacterial kill
Post-antibiotic effect (PAE): antibacterial activity persists after serum concentrations fall below MIC - the basis for once-daily dosing
The peak:MIC ratio and AUC:MIC ratio are the drivers of efficacy
Goodman & Gilman's, p. 1315-1317

4. Spectrum of Activity

Aminoglycosides are used primarily against aerobic gram-negative bacilli:

Pseudomonas aeruginosa (tobramycin most potent)
Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus
Staphylococcus aureus (synergistic with beta-lactams)
Enterococcus (synergistic with penicillin/ampicillin)
Mycobacterium tuberculosis (streptomycin, amikacin)

They have no activity against anaerobes, streptococci, or pneumococci.

5. Pharmacokinetics

Parameter	Details
Oral absorption	Negligible (must be given parenterally for systemic effect)
Distribution	Vd ~0.25 L/kg; poor CNS penetration; accumulates in renal cortex and inner ear
Protein binding	Very low
Metabolism	Minimal
Excretion	Almost entirely renal (glomerular filtration); urine concentrations 50-200 µg/mL
Half-life	2-3 hours (normal renal function); 20-40x longer in anephric patients
Neonates	t½ 8-11 hours (first week of life) - dose must be adjusted

Goodman & Gilman's, p. 1426-1430

6. Dosing Strategies

High-dose, extended-interval (once-daily) dosing is the preferred strategy for most indications. Rationale:

Exploits concentration-dependent killing (high peak/MIC ratio)
Exploits the PAE (activity persists between doses)
Reduces nephrotoxicity and ototoxicity by allowing drug concentrations in inner ear/kidney to fall below a threshold level between doses

Typical once-daily doses:

Gentamicin/tobramycin: 5-7 mg/kg
Amikacin: 15-25 mg/kg

Peak and trough levels must be monitored, especially in renal impairment. Traditional multiple-dosing (gentamicin 1-1.7 mg/kg every 8h; tobramycin 1-1.7 mg/kg every 8h) is reserved for certain indications like endocarditis synergy dosing.

7. Clinical Uses (General)

Indication	Agent(s)
Gram-negative sepsis, nosocomial infections	Gentamicin or tobramycin + beta-lactam
Hospital-acquired/VAP pneumonia	Aminoglycoside + beta-lactam (empiric)
Pseudomonas infections	Tobramycin or amikacin
Enterococcal endocarditis	Gentamicin + ampicillin (synergy)
Complicated UTI / pyelonephritis	Gentamicin or tobramycin
MDR-TB	Streptomycin or amikacin
Malignant otitis externa (fluoroquinolone-resistant)	Aminoglycoside + beta-lactam

8. Aminoglycosides in ENT (Major Focus)

8.1 Topical Use in Otitis Externa and Otitis Media

Topical preparations containing neomycin, gentamicin, and tobramycin have been used for decades in the ear canal to treat otitis externa (OE) and active chronic otitis media (COM). Common formulations include neomycin-polymyxin-hydrocortisone drops (Cortisporin), gentamicin ear drops, and others.

Key ENT-UK guidance: A topical aminoglycoside should only be used:

In the presence of obvious infection
For no longer than 2 weeks
Baseline audiometry should be performed before treatment where possible
Cummings Otolaryngology Head and Neck Surgery, p. 2665

Controversy with perforations: The risk of aminoglycoside-induced ototoxicity is a concern when there is a suspected or confirmed tympanic membrane perforation, because direct access to the round window membrane increases inner ear drug exposure. In such circumstances, many ENT surgeons prefer quinolone-based drops (ciprofloxacin or ofloxacin) as they have not demonstrated ototoxicity in animal or human data, and are the only topical agents FDA-approved for middle ear use.

However, an ENT-UK position paper stated that a short course of topical aminoglycoside in the presence of a perforation was acceptable because pus in the middle ear from otitis media carries a higher risk of ototoxicity than the drops themselves. The course must be short and stopped as soon as infection clears.

Scott-Brown's Otorhinolaryngology Head & Neck Surgery, p. 4713-4714
Cummings Otolaryngology, p. 2664-2665

Why human ototoxicity is lower than animal studies suggest:

Humans have thicker round window membranes
A deeper round window niche (greater protection)
A pseudomembrane may overlie the round window in chronic OM
Dilution by purulent fluids
Increased absorption into hyperemic mucosa
Clinical incidence of topical aminoglycoside-associated ototoxicity is estimated at ~1/10,000 patients

8.2 Malignant Otitis Externa

In ciprofloxacin-resistant Pseudomonas malignant OE, a third- or fourth-generation cephalosporin with or without an aminoglycoside may be required for systemic treatment. - Cummings Otolaryngology, p. 2665

8.3 Intratympanic Gentamicin for Meniere's Disease (Chemical Labyrinthectomy)

This is one of the most important and specific ENT applications of aminoglycosides.

Rationale: Gentamicin is preferentially vestibulotoxic over cochleotoxic. When injected through the tympanic membrane into the middle ear, it diffuses through the round window membrane into the perilymph and selectively ablates vestibular hair cell function. This is called partial chemolabyrinthectomy or chemical labyrinthectomy.

Indications:

Intractable unilateral Meniere's disease refractory to medical management
After failure of intratympanic dexamethasone (recommendation grade A per Scott-Brown's)
End-stage patients with drop attacks (Tumarkin crises)

Efficacy:

A 2012 meta-analysis (Huon et al.) confirmed 87.5% Class A and B vertigo control with intratympanic gentamicin
A 2012 RCT comparing intratympanic gentamicin vs dexamethasone: 93.5% substantial vertigo control with gentamicin at 2-year follow-up vs 61% with dexamethasone
Also effective for Tumarkin drop attacks

Technique: Injected into the middle ear space through the tympanic membrane, often using a small-bore needle via the anterior-inferior or posterior-inferior quadrant, with the patient in a specific head position to maximise round window exposure.

Complications:

Sensorineural hearing loss (SNHL): reported in 0-38.7% of cases - this is the main concern and must be discussed in counselling
Residual imbalance or visual-vestibular mismatch (expected consequence of vestibular ablation)
Patients no longer experience classic vertigo attacks but may develop disequilibrium

Outcome: The typical Meniere's vertigo attacks are abolished. The patient does not experience vertigo but may develop some imbalance.

Scott-Brown's Otorhinolaryngology Head & Neck Surgery Vol 2, p. 6321-6360
Cummings Otolaryngology, p. 2930

9. Ototoxicity - The Critical ENT Adverse Effect

Ototoxicity is the most clinically significant concern in ENT.

9.1 Mechanism

Aminoglycosides target cochlear and vestibular hair cells, entering in an energy-dependent process. The final common pathway is generation of reactive oxygen species (ROS) that destroy hair cells irreversibly. Because hair cells cannot regenerate in mammals, the damage is usually permanent.

9.2 Cochleotoxic vs Vestibulotoxic Agents

Drug	Predominant Toxicity
Gentamicin	Vestibulotoxic > cochleotoxic
Streptomycin	Vestibulotoxic > cochleotoxic
Neomycin	Cochleotoxic (most cochleotoxic; rapid and profound)
Kanamycin	Cochleotoxic > vestibulotoxic
Tobramycin	Cochleotoxic > vestibulotoxic
Amikacin	Cochleotoxic > vestibulotoxic
Dihydrostreptomycin	Cochleotoxic > vestibulotoxic

Cummings Otolaryngology, p. 2930

9.3 Pattern and Time Course

Hearing loss may be unilateral or asymmetric and can progress even after cessation of therapy (especially streptomycin, dihydrostreptomycin, tobramycin, amikacin, netilmicin, and gentamicin via middle ear route)
Neomycin toxicity is characteristically rapid and profound
Some reversibility may occur weeks to months after treatment

9.4 Risk Factors for Aminoglycoside Ototoxicity

Renal disease (reduced drug clearance)
Longer duration of therapy
Elevated serum levels (peak or trough)
Advanced age
Concomitant ototoxic drugs, especially loop diuretics (furosemide)
Mitochondrial 12S rRNA gene mutations (predispose to aminoglycoside ototoxicity)

9.5 Prevention and Monitoring

Routine monitoring of peak and trough serum levels
Use once-daily extended-interval dosing where possible
Avoid short dosing intervals
Baseline and serial audiometry for patients on prolonged therapy
Antioxidants show promise; aspirin (salicylates) has shown benefit in a placebo-controlled trial in China
Special vigilance during prolonged home-based IV antibiotic therapy

10. Nephrotoxicity

Approximately 8-26% of patients develop mild reversible renal impairment. The mechanism involves accumulation in proximal tubular cells:

Initial: tubular brush-border enzyme excretion, mild proteinuria
Progressive: reduced GFR
Usually non-oliguric and almost always reversible (proximal tubular cells can regenerate)

Toxicity correlates with total drug exposure and duration. Neomycin is the most nephrotoxic (should never be given systemically). Streptomycin is the least nephrotoxic. Risk is potentiated by amphotericin B, vancomycin, cisplatin, cyclosporine, and ACE inhibitors.

11. Other Adverse Effects

Neuromuscular blockade: rare but potentially fatal; patients with myasthenia gravis are particularly susceptible; reversed by IV calcium
Hypersensitivity: rare; cross-sensitivity within the class
Aminoglycosides should not be mixed with penicillins in the same IV bag (inactivation in vitro)

12. Resistance Mechanisms

Aminoglycoside-modifying enzymes (most common) - plasmid- or transposon-mediated acetyltransferases, nucleotidyltransferases, and phosphotransferases inactivate the drug; amikacin is most resistant to these
Impaired intracellular accumulation - reduced membrane permeability or efflux pumps
Ribosomal mutation - rare

Summary: ENT-Specific Applications at a Glance

Application	Drug	Route	Indication
Otitis externa	Neomycin, gentamicin, tobramycin	Topical	Acute & chronic OE (intact TM preferred)
Chronic suppurative OM	Gentamicin, tobramycin	Topical	Short course, infection present
Malignant OE (resistant)	Aminoglycoside + cephalosporin	IV	Fluoroquinolone-resistant Pseudomonas
Meniere's disease	Gentamicin	Intratympanic	Refractory vertigo, after medical failure
Chemical labyrinthectomy	Gentamicin	Intratympanic	End-stage disease, Tumarkin crises

Sources:

Cummings Otolaryngology Head and Neck Surgery (Primary ENT reference)
Scott-Brown's Otorhinolaryngology Head & Neck Surgery Vol 2
Goodman & Gilman's The Pharmacological Basis of Therapeutics (16th/17th ed.)
Katzung's Basic and Clinical Pharmacology, 16th Edition

This is a shared conversation. Sign in to Orris to start your own chat.